Patents by Inventor Stéphanie CHANTEUX

Stéphanie CHANTEUX has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMMUNOHISTOCHEMISTRY METHODS AND KIR3DL2-SPECIFIC REAGENTS
    Publication number: 20240117042
    Abstract: The present invention relates to antibodies and methods for detecting KIR3DL2 expression in paraffin-embedded tissue samples. Also provide are methods of making antibodies, antibody fragments, and derivatives thereof that specifically bind to their target antigen in paraffin-embedded tissue samples.
    Type: Application
    Filed: April 4, 2022
    Publication date: April 11, 2024
    Inventors: BENJAMIN ROSSI, STÉPHANIE CHANTEUX, ROMAIN REMARK, CÉCILE BONNAFOUS, CLARENCE DEFFAUD, THIBAUT PELAT
  • COMPOSITIONS AND METHODS FOR TREATING CANCER
    Publication number: 20230340143
    Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.
    Type: Application
    Filed: February 13, 2023
    Publication date: October 26, 2023
    Inventors: Stéphanie Chanteux, Nicolas Gourdin, Carine Paturel, Ivan Perrot, Benjamin Rossi
  • RESTORATION OF T CELL ACTIVITY VIA THE CD39/CD73 AXIS
    Publication number: 20230099801
    Abstract: The present invention relates to methods of using compounds that inhibit the enzymatic activity of soluble human CD39 to treat cancer, including but not limited to the treatment of cancers characterized by CD73 expressing cells.
    Type: Application
    Filed: July 28, 2022
    Publication date: March 30, 2023
    Inventors: Stéphanie CHANTEUX, Nicolas GOURDIN, Carine PATUREL, Ivan PERROT, Benjamin ROSSI
  • Compositions and methods for treating cancer
    Patent number: 11578136
    Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: February 14, 2023
    Assignees: INNATE PHARMA, OREGA BIOTECH
    Inventors: Stéphanie Chanteux, Nicolas Gourdin, Carine Paturel, Ivan Perrot, Benjamin Rossi
  • COMPOSITIONS AND METHODS FOR TREATING CANCER
    Publication number: 20230025732
    Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.
    Type: Application
    Filed: June 30, 2022
    Publication date: January 26, 2023
    Inventors: Stéphanie Chanteux, Laurent Gauthier, Nicolas Gourdin, Carine Paturel, Ivan Perrot, Benjamin Rossi
  • Antibodies that bind human CD39 and inhibit ATPase activity of a soluble extracellular domain human CD39 polypeptide
    Patent number: 11377503
    Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: July 5, 2022
    Assignee: INNATE PHARMA
    Inventors: Stéphanie Chanteux, Laurent Gauthier, Nicolas Gourdin, Carine Paturel, Ivan Perrot, Benjamin Rossi
  • LEUCOCYTE IMMUNOGLOBULIN-LIKE RECEPTOR NEUTRALIZING ANTIBODIES
    Publication number: 20220025056
    Abstract: This invention relates to agents that bind and neutralize the inhibitory activity of human ILT2 proteins having inhibitory activity in NK cells, T cells and/or other immune cells. Such agents can be used for the treatment of cancers or infectious disease.
    Type: Application
    Filed: December 20, 2019
    Publication date: January 27, 2022
    Inventors: OLIVIER BENAC, STÉPHANIE CHANTEUX, IVAN PERROT, BENJAMIN ROSSI, NICOLAS VIAUD
  • COMPOUNDS AND METHODS FOR TREATMENT OF HEAD AND NECK CANCER
    Publication number: 20220025045
    Abstract: This invention relates to the use of ILT-2-targeting agents for the treatment of cancers head and neck cancers. This invention also provides advantageous combination regimens for use with ILT-2-targeting agents for the treatment of cancers.
    Type: Application
    Filed: December 20, 2019
    Publication date: January 27, 2022
    Inventors: OLIVIER BENAC, STÉPHANIE CHANTEUX, IVAN PERROT, BENJAMIN ROSSI, NICOLAS VIAUD
  • COMPOSITIONS AND METHODS FOR TREATING CANCER
    Publication number: 20200024357
    Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.
    Type: Application
    Filed: June 17, 2019
    Publication date: January 23, 2020
    Inventors: Stéphanie Chanteux, Laurent Gauthier, Nicolas Gourdin, Carine Paturel, Ivan Perrot, Benjamin Rossi
  • COMPOSITIONS AND METHODS FOR TREATING CANCER
    Publication number: 20190389961
    Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.
    Type: Application
    Filed: March 16, 2018
    Publication date: December 26, 2019
    Inventors: Stéphanie Chanteux, Nicolas Gourdin, Carine Paturel, Ivan Perrot, Benjamin Rossi
  • RESTORATION OF T CELL ACTIVITY VIA THE CD39/CD73 AXIS
    Publication number: 20190218308
    Abstract: The present invention relates to methods of using compounds that inhibit the enzymatic activity of soluble human CD39 to treat cancer, including but not limited to the treatment of cancers characterized by CD73 expressing cells.
    Type: Application
    Filed: March 29, 2019
    Publication date: July 18, 2019
    Inventors: Stéphanie Chanteux, Nicolas Gourdin, Carine Paturel, Ivan Perrot, Benjamin Rossi
  • POTENTIATING THE EFFECT OF ATP RELEASE
    Publication number: 20190218304
    Abstract: The present invention relates to methods of using compounds that inhibit the enzymatic activity of soluble human CD39 in the treatment of cancer to potentiate the activity of an agent or treatment that induces the extracellular release of ATP from tumor cells and/or induces the death of tumor cells.
    Type: Application
    Filed: March 29, 2019
    Publication date: July 18, 2019
    Inventors: Stéphanie CHANTEUX, Nicolas GOURDIN, Carine PATUREL, Ivan PERROT, Benjamin ROSSI
  • CD73 BLOCKADE
    Publication number: 20180030144
    Abstract: This invention relates to antibodies that bind an epitope present on CD73 expressed at the surface of cells, including tumor cells, and that inhibit the enzymatic (ecto-5? nucleotidase) activity of the CD73 enzyme. Such agents can be used for the treatment of diseases such as cancers.
    Type: Application
    Filed: February 19, 2016
    Publication date: February 1, 2018
    Inventors: STEPHANIE CHANTEUX, CARINE PATUREL, IVAN PERROT, LAURENT GAUTHIER